Live price temporarily unavailable.
Autolus Therapeutics (AUTL) is a Health Care company. Latest news and coverage below.
| FY2016Sep 2016 | FY2017Sep 2017 | FY2018Sep 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.21M | $1.69M | $1.41M | $2.91M | — | — | — | $1.70M | $10.1M | $75.4M |
| Growth (year over year) | — | +39.7% | −16.9% | +106.7% | — | — | — | — | +496.0% | +644.9% |
| Gross profit | — | — | — | — | — | — | — | $1.70M | −$1.27M | −$21.0M |
| Gross margin | — | — | — | — | — | — | — | 100.0% | −12.5% | −27.8% |
| Operating income | — | −$23.4M | −$57.5M | −$146.1M | −$168.1M | −$141.1M | −$143.4M | −$179.7M | −$241.4M | −$270.5M |
| Operating margin | — | −1383.2% | −4089.1% | −5022.8% | — | — | — | −10583.1% | −2385.6% | −358.9% |
| Net income | −$12.6M | −$19.7M | −$44.8M | −$123.8M | −$142.1M | −$142.1M | −$148.8M | −$208.4M | −$220.7M | −$287.5M |
| Net margin | −1035.5% | −1165.2% | −3180.6% | −4258.9% | — | — | — | −12272.3% | −2180.5% | −381.4% |
| EPS (diluted) | −$1.26 | −$1.43 | −$1.42 | −$2.88 | −$2.76 | −$1.97 | −$1.57 | −$1.20 | −$0.86 | −$1.08 |
| Balance sheet | ||||||||||
| Cash and equivalents | $28.1M | $137.1M | $247.1M | $211.4M | $154.1M | $310.3M | $382.4M | $239.6M | $227.4M | $104.1M |
| Total assets | — | $148.7M | $273.2M | $303.5M | $294.2M | $405.6M | $490.3M | $375.4M | $782.7M | $589.1M |
| Total liabilities | — | $6.06M | $17.7M | $48.7M | $84.2M | $92.2M | $191.6M | $263.9M | $355.4M | $410.9M |
| Long-term debt | — | $763.0K | $380.0K | $0 | — | — | — | — | — | — |
| Shareholders' equity | $30.7M | $142.6M | $255.5M | $254.8M | $210.0M | $313.3M | $298.7M | $111.5M | $427.3M | $178.1M |
| Cash flow | ||||||||||
| Operating cash flow | −$9.85M | −$16.4M | −$31.5M | −$101.5M | −$117.8M | −$117.9M | −$112.3M | −$145.6M | −$206.3M | −$283.6M |
| Capital expenditure | $1.85M | $2.88M | $9.12M | $18.3M | $14.7M | $8.86M | $10.8M | $11.0M | $22.1M | $19.0M |
| Free cash flow | −$11.7M | −$19.2M | −$40.7M | −$119.8M | −$132.4M | −$126.7M | −$123.1M | −$156.6M | −$228.3M | −$302.6M |
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | $8.98M | $20.9M | $21.2M | $24.3M | $26.2M | $45.7M |
| Growth (year over year) | — | — | −11.0% | — | — | — | +191.9% | +118.4% |
| Gross profit | $0 | — | −$8.97M | −$3.52M | −$7.45M | −$1.04M | $1.65M | $25.2M |
| Gross margin | — | — | −99.9% | −16.8% | −35.1% | −4.3% | 6.3% | 55.2% |
| Operating income | −$67.9M | — | −$65.2M | −$61.2M | −$71.6M | −$72.5M | −$59.5M | −$43.8M |
| Operating margin | — | — | −726.3% | −292.6% | −337.9% | −298.3% | −227.0% | −95.9% |
| Net income | −$82.1M | — | −$70.2M | −$47.9M | −$79.1M | −$90.3M | −$71.6M | −$39.1M |
| Net margin | — | — | −781.1% | −229.0% | −373.3% | −371.9% | −273.1% | −85.6% |
| EPS (diluted) | −$0.31 | — | −$0.26 | −$0.18 | −$0.30 | −$0.34 | −$0.27 | −$0.15 |
| Balance sheet | ||||||||
| Cash and equivalents | $657.1M | $227.4M | $95.8M | $123.8M | $86.1M | $104.1M | $130.9M | $171.4M |
| Total assets | $827.5M | $782.7M | $746.3M | $721.0M | $661.9M | $589.1M | $527.1M | $493.2M |
| Total liabilities | $350.5M | $355.4M | $375.2M | $374.5M | $396.5M | $410.9M | $418.2M | $418.4M |
| Shareholders' equity | $477.0M | $427.3M | $371.1M | $346.5M | $265.5M | $178.1M | $108.8M | $74.8M |
| Cash flow | ||||||||
| Operating cash flow | −$76.7M | — | −$75.6M | −$72.8M | −$67.9M | −$67.3M | −$65.3M | −$25.1M |
| Capital expenditure | $9.59M | — | $8.24M | $7.28M | $4.41M | −$885.0K | $2.69M | $913.0K |
| Free cash flow | −$86.3M | — | −$83.8M | −$80.1M | −$72.3M | −$66.4M | −$68.0M | −$26.0M |
From Autolus Therapeutics's 10-K, 10-Q, 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Autolus Therapeutics in our feed yet.